Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Making a national donor research program a reality: Concepts for operationalizing a system.

Freeman RB.

Am J Transplant. 2019 Jul 23. doi: 10.1111/ajt.15536. [Epub ahead of print]

PMID:
31334906
2.

Share capitalism and worker wellbeing.

Bryson A, Clark AE, Freeman RB, Green CP.

Labour Econ. 2016 Oct;42:151-158. doi: 10.1016/j.labeco.2016.09.002. Epub 2016 Sep 14.

3.

Characteristics and outcomes of neutropenia after orthotopic liver transplantation.

Alraddadi B, Nierenberg NE, Price LL, Chow JK, Poutsiaka DD, Rohrer RJ, Cooper JT, Freeman RB, Snydman DR.

Liver Transpl. 2016 Feb;22(2):217-25. doi: 10.1002/lt.24332.

4.

Invited commentary.

Freeman RB Jr.

J Am Coll Surg. 2015 Jun;220(6):1007-9. doi: 10.1016/j.jamcollsurg.2015.03.011. No abstract available.

PMID:
25998078
5.

Collaboration: Strength in diversity.

Freeman RB, Huang W.

Nature. 2014 Sep 18;513(7518):305. doi: 10.1038/513305a. No abstract available.

PMID:
25230634
6.

Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation.

Nierenberg NE, Poutsiaka DD, Chow JK, Cooper J, Price LL, Freeman RB, Rohrer R, Snydman DR.

Liver Transpl. 2014 Dec;20(12):1497-507. doi: 10.1002/lt.23991.

7.

Invited commentary.

Freeman RB Jr.

J Am Coll Surg. 2014 Jun;218(6):1118-9. doi: 10.1016/j.jamcollsurg.2014.03.006. No abstract available.

PMID:
24840682
8.

Deceased donor risk factors influencing liver transplant outcome.

Freeman RB.

Transpl Int. 2013 May;26(5):463-70. doi: 10.1111/tri.12071. Epub 2013 Feb 18. Review.

9.

The limits of altruism: selecting living donors.

Freeman RB Jr.

Virtual Mentor. 2012 Mar 1;14(3):272-7. doi: 10.1001/virtualmentor.2012.14.3.oped1-1203. No abstract available.

10.

Ethical issues in organ transplantation.

Freeman RB, Bernat JL.

Prog Cardiovasc Dis. 2012 Nov-Dec;55(3):282-9. doi: 10.1016/j.pcad.2012.08.005. Review.

PMID:
23217432
11.

A decade of model for end-stage liver disease: lessons learned and need for re-evaluation of allocation policies.

Freeman RB.

Curr Opin Organ Transplant. 2012 Jun;17(3):211-5. doi: 10.1097/MOT.0b013e3283534dde. Review.

PMID:
22516923
12.

Transplantation: Sharing of donated livers is not equal.

Freeman RB.

Nat Rev Gastroenterol Hepatol. 2012 Apr 17;9(5):248-9. doi: 10.1038/nrgastro.2012.69. No abstract available.

PMID:
22508162
13.

A consolidated biovigilance system for blood, tissue and organs: one size does not fit all.

Pruett TL, Blumberg EA, Cohen DJ, Crippin JS, Freeman RB, Hanto DW, Mulligan DC, Green MD.

Am J Transplant. 2012 May;12(5):1099-101. doi: 10.1111/j.1600-6143.2011.03907.x. Epub 2012 Apr 9.

14.

Should we change the priority for liver allocation for patients with the highest MELD score?

Freeman RB, Wiesner R.

Hepatology. 2012 Jan;55(1):14-5. doi: 10.1002/hep.24775. No abstract available.

PMID:
22095707
15.

Variation in health care delivery: the example of exception awards in liver transplantation.

Freeman RB Jr.

Am J Transplant. 2011 Nov;11(11):2271-2. doi: 10.1111/j.1600-6143.2011.03740.x. Epub 2011 Sep 15. No abstract available.

16.

The impact of variation in donation after cardiac death policies among donor hospitals: a regional analysis.

Rhee JY, Ruthazer R, O'Connor K, Delmonico FL, Luskin RS, Freeman RB.

Am J Transplant. 2011 Aug;11(8):1719-26. doi: 10.1111/j.1600-6143.2011.03634.x. Epub 2011 Jul 12.

17.

Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement.

Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB.

Liver Transpl. 2011 Oct;17 Suppl 2:S81-9. doi: 10.1002/lt.22380. Review. No abstract available.

18.

Small steps versus big leaps in changing liver distribution policy.

Freeman RB Jr.

Liver Transpl. 2011 Sep;17(9):991-2. doi: 10.1002/lt.22376. No abstract available.

19.

Characterization of the withdrawal phase in a porcine donation after the cardiac death model.

Rhee JY, Alroy J, Freeman RB.

Am J Transplant. 2011 Jun;11(6):1169-75. doi: 10.1111/j.1600-6143.2011.03567.x.

20.

The price of "doing the right thing".

Freeman RB Jr.

Liver Transpl. 2011 Jun;17(6):631-2. doi: 10.1002/lt.22253. No abstract available.

21.

Comparative analysis of outcome in patients with hepatocellular carcinoma exceeding the milan criteria treated with liver transplantation versus partial hepatectomy.

Canter RJ, Patel SA, Kennedy T, D'Angelica MI, Jarnagin WR, Fong Y, Blumgart LH, Freeman RB, DeMatteo RP, Abt PL.

Am J Clin Oncol. 2011 Oct;34(5):466-71. doi: 10.1097/COC.0b013e3181ec63dd.

PMID:
20938319
22.

Successful outcomes following living donor liver transplantation for portopulmonary hypertension.

Bandara M, Gordon FD, Sarwar A, Knauft ME, Pomfret EA, Freeman RB, Wirth JA.

Liver Transpl. 2010 Aug;16(8):983-9. doi: 10.1002/lt.22107.

23.

Transplant data collection: you get what you pay for.

Freeman RB.

Am J Transplant. 2010 Jul;10(7):1503-4. doi: 10.1111/j.1600-6143.2010.03144.x. No abstract available.

24.

Biologic markers as predictors for liver transplant outcome.

Freeman RB.

Am J Transplant. 2010 Jan;10(1):10-1. doi: 10.1111/j.1600-6143.2009.02878.x. Epub 2009 Nov 24. No abstract available.

25.

The 'indirect' effects of cytomegalovirus infection.

Freeman RB Jr.

Am J Transplant. 2009 Nov;9(11):2453-8. doi: 10.1111/j.1600-6143.2009.02824.x. Review.

26.

Overcoming the ABO incompatibility barrier.

Freeman RB Jr.

Liver Transpl. 2009 Aug;15(8):831-3. doi: 10.1002/lt.21752. No abstract available.

27.

ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation.

Reich DJ, Mulligan DC, Abt PL, Pruett TL, Abecassis MM, D'Alessandro A, Pomfret EA, Freeman RB, Markmann JF, Hanto DW, Matas AJ, Roberts JP, Merion RM, Klintmalm GB; ASTS Standards on Organ Transplantation Committee.

Am J Transplant. 2009 Sep;9(9):2004-11. doi: 10.1111/j.1600-6143.2009.02739.x. Epub 2009 Jul 16.

28.

Stimulus for organ donation: a survey of the American Society of Transplant Surgeons membership.

Rodrigue JR, Crist K, Roberts JP, Freeman RB Jr, Merion RM, Reed AI.

Am J Transplant. 2009 Sep;9(9):2172-6. doi: 10.1111/j.1600-6143.2009.02741.x. Epub 2009 Jul 16.

29.

The value of machine perfusion in deceased donor kidney transplantation.

Cooper JT, Freeman RB.

Am J Kidney Dis. 2009 Sep;54(3):410-2. doi: 10.1053/j.ajkd.2009.05.004. Epub 2009 Jun 28. No abstract available.

PMID:
19560851
30.

Moving kidney allocation forward: the ASTS perspective.

Freeman RB, Matas AT, Henry M, Segev DL, Kaufman DB, Roberts JP.

Am J Transplant. 2009 Jul;9(7):1501-6. doi: 10.1111/j.1600-6143.2009.02697.x. Epub 2009 Jun 10.

31.

Organ donation.

Rhee J, Kern B, Cooper J, Freeman RB.

Semin Liver Dis. 2009 Feb;29(1):19-39. doi: 10.1055/s-0029-1192053. Epub 2009 Feb 23. Review.

PMID:
19235657
32.

Who should get a liver graft?

Freeman RB, Jamieson N, Schaubel DE, Porte RJ, Villamil FG.

J Hepatol. 2009 Apr;50(4):664-73. doi: 10.1016/j.jhep.2009.01.013. Epub 2009 Feb 12. No abstract available.

33.

Transplantation risks and the real world: what does 'high risk' really mean?

Freeman RB, Cohen JT.

Am J Transplant. 2009 Jan;9(1):23-30. doi: 10.1111/j.1600-6143.2008.02476.x. Epub 2008 Nov 27. Review.

34.

SOFT endpoints in liver transplantation.

Freeman RB Jr.

Am J Transplant. 2008 Dec;8(12):2483-4. doi: 10.1111/j.1600-6143.2008.02452.x. No abstract available.

35.

Report of the Paris consensus meeting on expanded criteria donors in liver transplantation.

Durand F, Renz JF, Alkofer B, Burra P, Clavien PA, Porte RJ, Freeman RB, Belghiti J.

Liver Transpl. 2008 Dec;14(12):1694-707. doi: 10.1002/lt.21668. Review.

36.

Donor postextubation hypotension and age correlate with outcome after donation after cardiac death transplantation.

Ho KJ, Owens CD, Johnson SR, Khwaja K, Curry MP, Pavlakis M, Mandelbrot D, Pomposelli JJ, Shah SA, Saidi RF, Ko DS, Malek S, Belcher J, Hull D, Tullius SG, Freeman RB, Pomfret EA, Whiting JF, Hanto DW, Karp SJ.

Transplantation. 2008 Jun 15;85(11):1588-94. doi: 10.1097/TP.0b013e318170b6bb.

PMID:
18551064
37.

Liver and intestine transplantation in the United States, 1997-2006.

Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM.

Am J Transplant. 2008 Apr;8(4 Pt 2):958-76. doi: 10.1111/j.1600-6143.2008.02174.x.

38.

Liver transplantation for hepatocellular carcinoma: racial disparities?

Freeman RB.

Am J Gastroenterol. 2008 Jan;103(1):128-30. doi: 10.1111/j.1572-0241.2007.01630.x.

PMID:
18184120
39.

"Transplant tourism" in the United States?

Freeman RB.

Transplantation. 2007 Dec 27;84(12):1559-60. doi: 10.1097/01.tp.0000296818.13150.aa. No abstract available.

PMID:
18165763
40.

Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card.

Freeman RB Jr.

Hepatology. 2008 Mar;47(3):1052-7. Review. No abstract available.

PMID:
18161047
41.

L-[1-(13)C] phenylalanine breath test for monitoring hepatic function after living donor liver transplant surgery.

Freeman RB, Dixon M, Horth B, Melanson AM, Palladino MB, Kinzel J, Rohrer R, Cooper J, Reid J, Modak AS.

J Breath Res. 2007 Dec;1(2):026002. doi: 10.1088/1752-7155/1/2/026002. Epub 2007 Nov 8.

PMID:
21383436
42.

Predicting the future?

Freeman RB Jr.

Liver Transpl. 2007 Nov;13(11):1503-5. No abstract available.

43.
44.

Justice, administrative law, and the transplant clinician: the ethical and legislative basis of a national policy on donor liver allocation.

Barshes NR, Hacker CS, Freeman RB Jr, Vierling JM, Goss JA.

J Contemp Health Law Policy. 2007 Spring;23(2):200-30. No abstract available.

PMID:
17642381
45.

The model for end-stage liver disease comes of age.

Freeman RB Jr.

Clin Liver Dis. 2007 May;11(2):249-63. Review.

PMID:
17606205
46.

Survival benefit: quality versus quantity and trade-offs in developing new renal allocation systems.

Freeman RB Jr.

Am J Transplant. 2007 May;7(5):1043-6. Epub 2007 Mar 12. No abstract available.

47.

Model for end-stage liver disease (MELD) exception guidelines.

Wiesner R, Lake JR, Freeman RB, Gish RG.

Liver Transpl. 2006 Dec;12(12 Suppl 3):S85-7. No abstract available. Erratum in: Liver Transpl. 2008 Sep;14(9):1386.

48.

Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.

Freeman RB Jr, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, Klintmalm G, Blazek J, Hunter R, Punch J.

Liver Transpl. 2006 Dec;12(12 Suppl 3):S128-36. No abstract available. Erratum in: Liver Transpl. 2008 Sep;14(9):1386.

49.

Fetal cells participate over time in the response to specific types of murine maternal hepatic injury.

Khosrotehrani K, Reyes RR, Johnson KL, Freeman RB, Salomon RN, Peter I, Stroh H, Gu├ęgan S, Bianchi DW.

Hum Reprod. 2007 Mar;22(3):654-61. Epub 2006 Oct 30.

PMID:
17074776
50.

Transplantation for hepatocellular carcinoma: The Milan criteria and beyond.

Freeman RB Jr.

Liver Transpl. 2006 Nov;12(11 Suppl 2):S8-13. Review.

Supplemental Content

Loading ...
Support Center